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The self-inhibitory nature of metabolic networks
and its alleviation through compartmentalization
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Aleksej Zelezniak1,5,6, Ben F. Luisi1 & Markus Ralser1,5
Metabolites can inhibit the enzymes that generate them. To explore the general nature of
metabolic self-inhibition, we surveyed enzymological data accrued from a century
of experimentation and generated a genome-scale enzyme-inhibition network. Enzyme
inhibition is often driven by essential metabolites, affects the majority of biochemical
processes, and is executed by a structured network whose topological organization is
reﬂecting chemical similarities that exist between metabolites. Most inhibitory interactions
are competitive, emerge in the close neighbourhood of the inhibited enzymes, and result from
structural similarities between substrate and inhibitors. Structural constraints also explain
one-third of allosteric inhibitors, a ﬁnding rationalized by crystallographic analysis of
allosterically inhibited L-lactate dehydrogenase. Our ﬁndings suggest that the primary
cause of metabolic enzyme inhibition is not the evolution of regulatory metabolite–enzyme
interactions, but a ﬁnite structural diversity prevalent within the metabolome. In eukaryotes,
compartmentalization minimizes inevitable enzyme inhibition and alleviates constraints
that self-inhibition places on metabolism.
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T
he activity of metabolic enzymes depends on their
structure, but also on their chemical environment
and non-catalytic metabolite–enzyme interactions with
inhibitors and activators1,2. Metabolic enzyme inhibition enables
feedback and feedforward loops important in the regulation
of metabolism2–5. Some of the best studied examples are
found within central metabolism6, and include the production
of a unique regulatory metabolite, fructose-2,6-bisphosphate
that controls glycolysis7,8, or fructose-1,6-bisphosphate which,
as a metabolite correlated with ﬂux3, acts as an allosteric feed-
forward activator of glycolysis ATP net-producing enzyme,
pyruvate kinase (PK)9.
However, the evolutionary origins of metabolic enzyme inhibition
are neither, in essence, explained by the need to regulate metabolism,
nor are the general principles that guide metabolic enzyme
inhibition. Metabolic feedback inhibition for instance can be a
direct consequence of the catalytic mechanisms itself10. In other
instances, distally produced metabolites act as inhibitors by having
strong structural similarity with the enzymatic substrates. For
instance, phosphoenolpyruvate inhibits triosephosphate isomerase
(TPI) due to extensive structural similarity with dihydroxyacetone
phosphate, which constrains the activity of glycolysis when cells
respire5,11. This and other self-regulatory metabolite–enzyme
interactions have been incorporated into mathematical models,
upon which a much better quantitative reﬂection of metabolic
functionality is achieved12–15. Enzymes hence participate in a fully
functional metabolism while being partially inhibited.
As studying enzyme inhibition remains a laborious and mostly
in vitro process, there is little information about its global nature.
In order to obtain insights into the principles of metabolic
self-inhibition, we curated and combined comprehensive
enzymological knowledge obtained over a century of biochemical
research, that has been collected in the Braunschweig Enzyme
Database (BRENDA) database16 with a genome-scale reconstru-
ction of the human metabolism17. We obtained a highly
structured enzyme-inhibition network that shows inhibition is
predominantly emerging from chemical structural constraints.
With different metabolite chemical specimen affecting speciﬁc
enzyme classes, metabolic enzyme inhibition is found to be an
extremely frequent phenomenon that affects virtually all
biochemical process. We provide evidence that metabolic
enzyme inhibition constraints metabolism to the extent that
cells evolve to minimize unwanted metabolite–enzyme intera-
ctions. A key mechanism is identiﬁed with the speciﬁc organellar
localization of enzymes in eukaryotic cells, that prevents an
enrichment of metabolic–enzyme inhibition within the organellar
metabolic neighbourhood.
Results
A metabolome-scale enzyme-inhibition network. Over a period
of nearly 30 years, the BRENDA database16 has collected 201,940
reference citations and 170,794 enzyme entries associated
with 6,763 Enzyme Commission (EC) classes (as of July 2015),
summarizing enzymology data that dates back to the beginning
of biochemical research. After curation of this data set, we were
able to map 30,107 inhibitors to 685 of 747 (91.7%) biochemical
reactions (EC numbers) contained in the human metabolic
network reconstruction Recon2 (ref. 17). The median number
of inhibitors per reaction is 29, spanning over a broad range.
Sixteen enzymes have just one inhibitor assigned, while the most
extreme case is monoamine oxidase (EC:1.4.3.4) with 1,017
inhibitors.
Next, we removed all entries that could not be matched to a
unique metabolite (KEGG, HMDB identiﬁers), and restricted
the network to those inhibitors that are human metabolites.
This core of the data set consists of 1,311 studies which
were speciﬁcally conducted on 333 human enzymes and 431
human metabolites. Then, we expanded the network to include
‘cross-species’ data, exploiting the fact that the principles which
guide enzyme inhibition are the same across species (Fig. 1a).
In this way we obtained a network in sufﬁcient coverage to
derive general principles. Indeed, inhibitors are in most cases
not speciﬁc to one species (that is, refs 18–21), and we revealed
that more than half (693/1,311 (53%)) of human metabolic
inhibitors were experimentally reported in at least one other
species as well. In the ﬁnal network, 10.3% of all edges are based
on human-only experiments, and 21.9% are derived from
inhibitors reported on both the human enzyme as well as at
least one other species.
Retaining the topological organization and chemical
make-up of the human metabolic network, the cross-species
informed inhibitor network consists of 682 metabolic inhibitors
(mapping to 26% of human metabolites) that inhibit 83% (621)
of its distinct enzymatic reactions (Fig. 1a,b, Supplementary
Data 1). The bipartite inhibition network consists of 5,989
edges associated with 1,303 nodes. It possesses scale-free structure
(degree distribution empirically follows a power-law distribution
with parameter 2ogo3, compared to a random network
where g¼ 11.47; Fig. 1c) and has characteristics of a typical
non-random biological network. The most connected inhibitor
is ATP (maximum connectivity 167), while 90% of enzymes
and inhibitors have 20 or less connections (Fig. 1c).
Owing to the rich amount of data, each enzyme EC category
is similarly well covered by inhibitor information. In all, 208 out
of 244 transferases are inhibited by at least one metabolite,
159 out of 205 oxidoreductases, 147 out of 161 hydrolases,
49 out of 66 lyases, 32 out of 39 isomerases, and 26 out of the
28 ligases (Fig. 1c,d, Supplementary Table 1). All enzyme classes
are found similarly susceptible to metabolic inhibition; most
inhibited class of enzymes was also the largest enzyme class,
transferases (1964, or 32.8%, of all inhibitor interactions) followed
by oxidoreductases (1656; 27.7%), hydrolases (1388; 23.2%),
lyases (496; 8.3%), ligases (293; 4.9%), and isomerases (188; 3.1%)
(Supplementary Table 1).
To classify the inhibitors, we adopted the chemical categoriza-
tions of the human metabolome database (HMDB 3.5)22, merging
small superclasses to yield eight groups of chemical similarity
(Supplementary Table 2): ‘Lipids’ (178 out of the 610 lipids)
account for most inhibitions, followed by ‘Aromatic Cyclic
Compounds’ (105 out of 161), ‘Amino Acids, Peptides and
Analogues’ (85 out of 176), ‘Nucleosides, Nucleotides and
Analogues’ (84 out of 102), ‘Carbohydrates and Carbohydrate
Conjugates’ (63 out of 98), ‘Organic Acids and Derivatives’
(43 out of 69), ‘Aliphatic Acyclic Compounds’ (40 out of 65) plus
all ‘other compounds’ (84 out of 376) (Fig. 1d, Supplementary
Table 2). Twenty-nine per cent (197/682) of the inhibitors were
phosphorylated. This includes 83.3% of ‘Nucleosides, Nucleotides
and Analogues’, 36.5% of ‘Carbohydrates and Carbohydrate
Conjugates’, 26.4% of ‘Lipids’ and 3.5% of ‘Amino Acids, Peptides
and Analogues’ category (Supplementary Table 2).
As metabolites can inhibit multiple enzymes, the number
of inhibitory interactions is substantially different to the
number of inhibitors per metabolite class. Thirty per cent of all
inhibitor interactions are accountable to ‘Nucleosides, Nucleo-
tides, and Analogues’ (1,749 inhibitory interactions), followed by
‘Lipids’ (810; 13.5%), ‘Amino Acids, Peptides, and Analogues’
(613; 10.2%), ‘Aromatic Cyclic Compounds’ (592; 9.9%),
‘Aliphatic Acyclic Compounds’ (541; 9%), ‘Organic Acids and
Derivatives’ (537; 9%) and ‘Carbohydrates and Carbohydrate
Conjugates’ (375; 6.2%), and a total of 721 (12.9%) by other
metabolites (Supplementary Table 2). The dominance of
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‘Nucleosides, Nucleotides, and Analogues’ is also reﬂected on the
level of the most potent single inhibitors, adenylate and
nicotinamide nucleotides (Fig. 1e, Supplementary Data 1). While
these absolute numbers are subject to testing bias, a statistical
analysis that corrects for the sample size conﬁrmed the dominant
role of nucleotide inhibitors, that are not only the most frequent
inhibitors but also the most metabolically connected metabolites.
Importantly, the chemical identity of the inhibitors was found
to reveal the enzyme class they most likely inhibit (Fig. 1f,
Supplementary Tables 3–5). ‘Nucleosides, Nucleotides, and
Analogues’ are signiﬁcantly enriched to inhibit Transferases and
Ligases (P value 4.8e 34 and 0.01 respectively), ‘Amino Acids,
Peptides, and Analogues’ to inhibit Lyases (P value 1.8e-03),
‘Carbohydrates and Carbohydrate Conjugates’ to inhibit
Isomerases and Hydrolases (P values 5.9e-18 and 6.7e-11,
respectively); ‘Lipids’ inhibit Oxidoreductases and Isomerases
(P values 2.3e-04 and 2.9e-02); ‘Organic Acids and Derivatives’
inhibit Oxidoreductases, Ligases and Lyases (P values 5.3e-20,
3.1e-02 and 6e-03), ‘Aliphatic Acyclic Compounds’ inhibit
Oxidoreductases and Hydrolases (P values 2e-2 and 1.2e-3);
and ﬁnally ‘Aromatic Cyclic Compounds’ inhibit Oxidoreduc-
tases and Lyases (P values 1.5e-15 and 2.9e-2) (Fig. 1f, Suppleme-
ntary Tables 3–5). Despite the inhibition network includes
also weak inhibitors as stored in BRENDA, and its underlying
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Figure 1 | A genome-scale network of enzyme inhibition. (a) construction of a genomic-scale enzyme-inhibition network by mapping inhibitor information
curated from the BRENDA database16, to the human metabolic reconstruction (Recon2 (ref. 17)). (b) enzyme-inhibition network (non-directional
illustration), in which 82% of enzymatic reactions are inhibited by 26% of Recon2 metabolites. Enzymes are coloured and grouped according to enzyme
commission (EC) category, inhibitors according to their HMDB chemical classiﬁcation22, node size is scaled numerically. (c) The enzyme-inhibition
network is scale-free, and follows a power-law and a log-normal distribution (P value for comparing power-law distribution with log-normal, Poisson and
exponential are 0.36, 8.7e-05, 0.077 respectively), in comparison to a random network of the same size which is not scale-free (P value for comparing
power-law distribution with log-normal, Poisson and exponential are 0.42, 0.78, 0.44, respectively). Ninety per cent of enzymes and metabolites have 20
or less connections (blue line). (d) Top: Enzyme classes (EC classiﬁcations) according to their occurrence in the genome, in relation to their representation
in the inhibition network. Bottom: Metabolites categorized according to HMDB superclass22, and the percentage, and to which extent they are inhibitors in
b. (e) Fifty most frequently inhibiting metabolites illustrated as word-cloud, scaled to the number of inhibitory interactions annotated for each inhibitor.
(f) Enzyme classes are inhibited dependent on the metabolite’s chemistry. Size of the nodes is scaled according the number of inhibitor/enzymes within
each class. The edge thickness is scaled according to the occurrence of signiﬁcant inhibitory interactions between the inhibitor’s superclass, and enzyme
class. Nodes are connected if P valueo0.05. FDR values are highlighted over edges. Abbreviations refer to HMDB categories: Amino acids, Amino Acids,
Peptides and Analogues; Aliphatic comp., Aliphatic Acyclic Compounds; Aromatic comp., Aromatic Cyclic Compounds; Carbohydrates, Carbohydrates and
Carbohydrate Conjugates; Organic acids, Organic Acids and Derivatives; Nucleotides, Nucleosides, Nucleotides and Analogues.
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data are subject to literature bias, the network reveals highly
distinct topology that is dependent on the chemical class of the
metabolites.
Competitive inhibition dominates metabolism. The biochem-
ical literature distinguishes three major inhibitory mechanisms:
competitive, noncompetitive and uncompetitive (or metabolic
allostery). Of these, competitive inhibition implies indeed
a structural relationship between inhibitor and substrate23,24.
We questioned which mechanisms would dominate. We
manually curated the data set to create a ‘gold standard’ of
single-experiment determined reaction mechanisms. Competitive
inhibition accounted for 74.6% of the gold-standard mechanisms,
noncompetitive for 18.6% and uncompetitive inhibition for
merely 6.7% (Fig. 2a). We selected three representative
examples TPI, aconitase and PK, for which crystallographic
structures both for the enzymes bound to substrate and
competitive inhibitor are available5,25–29. In all three cases, the
structures revealed striking structural similarity with a metabolic
substrate (Fig. 2d).
Next, we used computational structure prediction to enumerate
similarities between substrates and inhibitors. Pairwise
compound comparisons with ﬁngerprint similarity (fpSim30),
drug molecule similarity derived by molecular ﬁngerprints
(calcDrugFPSim31), maximum common substructure (Tanimoto
Coefﬁcient, Overlap Coefﬁcient32) as well as pairwise compound
comparisons with atom pairs (cmp.similarity30), all revealed that
the typical competitive inhibitor possesses signiﬁcant similarity to
at least one enzymatic substrate in the gold-standard data set
(Fig. 2b P value 2.84e-06, Supplementary Fig. 1).
For most inhibitory interactions that constitute our network
the mechanism is unknown. However signiﬁcant similarity
between inhibitor and at least one substrate is detected
across the entire network. Vice versa, even the most similar
metabolite out of a poolsize-corrected random sampling
lacks structural similarity (Fig. 2c, Supplementary Fig. 2).
Most of metabolic enzyme inhibition is hence explained by
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Figure 2 | Enzyme inhibition across the metabolic landscape is driven by structural similarity between metabolites. (a) Gold-standard set: Competitive
inhibition is the most common type of inhibition (74.6%) followed by noncompetitive (18.6%) and then by uncompetitive inhibition (6.7%), across 462
examples determined in individual enzymological experiments (Supplementary Data 1). (b) Pairwise compound similarity (fpSim) between inhibitor and
substrate reveals signiﬁcant structural similarity (0¼ non-similar, 1¼maximum possible structural similarity). The median similarity for allosteric inhibitors
is not signiﬁcantly different to that of a random inhibitor; however, the spread is much higher, with a about 1/3rd of allosteric inhibitors being as similar
enzyme’s metabolic substrates as competitive inhibitors. (c) The genome-scale set of enzymatic inhibitors have a wide range of similarities including highly
similar metabolite–inhibitor relationships (ranging from 0.2–1), compared to random substrates, which are not structurally similar (0.2–0.4). (d) Three
selected examples (protein/metabolite structure determined by X-ray crystallography) revealing the extent of structural similarity between competitive
inhibitor and substrate in the active site of key enzymes. (i) Triosephosphate isomerase (TPI: 1NEY, inhibitor: 4OWG (ref. 5)); Substrate: Dihydroxyacetone
phosphate (DHAP); Inhibitor: phosphoenolpyruvate (PEP), (ii) Enzyme: Aconitase (ACO: 1C96 (ref. 28), inhibitor: 1ACO (ref. 29)); Substrate: Citrate (CIT);
Inhibitor: Trans-aconitate (TRA), (iii) Enzyme: Pyruvate Kinase (PK: 4HYV (ref. 26), inhibitor: 4IP7 (ref. 27)); Substrate: phosphoenolpyruvate (PEP);
Inhibitor: Citrate (CIT).
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structural similarity between substrates and other cellular
metabolites.
Enzymes have not been exhaustively tested against all
metabolites. We hence computed structural similarity coefﬁcients
for all metabolite pairs within the metabolic network. Considering
the average structural similarity between substrate and inhibitor
as cut-off, 97.7% of human metabolites (1,338 out of 1,369
compounds, with Kegg/HMDB ID) are structurally similar to
at least one other human metabolite. A conﬁned chemical
structural diversity within the metabolome makes in essence
every enzymatic reaction susceptible to competitive inhibition.
Many allosteric inhibitors resemble the substrate structure.
Non-competitive and uncompetitive enzyme inhibition is not
dependent on structural similarity between substrate and
inhibitor, as the inhibitor does bind to a different site in the enzyme.
Nonetheless, 33% of non-competitive and 31% uncompetitive
inhibitors are structurally similar to the enzyme’s substrates (Fig. 2b,
Supplementary Fig. 1). One illustrative example was identiﬁed with
L-lactate dehydrogenase (L-LDH). L-LDH is allosterically inhibited
by its substrate, pyruvate33,34. However, also malonate, not a typical
intermediate of mammalian metabolism, is a non-competitive
inhibitor35. Further, oxaloacetate has been reported to inhibit
L-LDH as well36–38. We performed computational similarity
calculations, and found that pyruvate, malonate and oxaloacetate
all are structurally highly similar (Malonate pyruvate
similarity¼ 0.667, substructure overlap¼ 0.834; Oxaloacetate
pyruvate similarity¼ 0.685, substructure overlap¼ 1; and
MalonateOxaloacetate similarity¼ 0.685, substructure overlap¼
0.857 (similarity¼ ‘Pairwise compound comparisons with
PubChem ﬁngerprints’30; substructure overlap¼ ‘Maximum
common substructure Overlap Coefﬁcient’)32.
In order to test whether structural similarity could explain
the allosteric inhibition, L-LDH puriﬁed from rabbit muscle was
co-crystallized with oxaloacetate and NADH, or malonate,
respectively. The structures were solved by X-ray crystallography
followed by molecular replacement, and reﬁned at 1.87 and
1.58Å resolution, respectively (reﬁnement statistics in Table 1).
Malonate and oxaloacetate bind L-LDH in a similar fashion as the
structurally similar pyruvate. L-LDH forms a tetramer and a
complete tetramer occupies the asymmetric unit for both crystals
(Fig. 3a). Analysing the electron density map of L-LDH
co-crystallized with oxaloacetate and NADH, we could identify
oxaloacetate at partial occupancy in two of the four subunits
(Fig. 3a). Oxaloacetate forms a hydrogen bond network with
R105, R168, H192, N137, T247 and numerous water molecules.
Electron density for malonate at partial occupancy was present in
three of the subunits for the crystal grown without the cofactor
NADH (Fig. 3a). Both inhibitors bind adjacent to, but not within,
the active site (Fig. 3b,c) and interact with the same amino
acids (Fig. 3d). Moreover, electron densities corresponding to
two malonates were present in the interface between chains A and
C and between B and D. These ligands form hydrogen bond
interactions with R170 from one chain and S183, H185 of the
other chain and various water molecules. However, no inhibitor
was found in the interface of L-LDH when co-crystallized
with oxaloacetate and NADH. Instead, sulfate ions were present
in the same location interacting with R170, H185 of one chain
and H185 of the other (Fig. 3a).
Next, we determined the kinetic mechanism in vitro and
found L-LDH inhibition by malonate to match the model of
non-competitive inhibition (R2 of 0.93). The Km obtained for
pyruvate and NADH were 0.300±0.035 and 0.095±0.012mM,
respectively. Moreover, we ﬁnd that, similar to malonate,
oxaloacetate is a non-competitive inhibitor of L-LDH with
respect to pyruvate with moderate in vitro inhibition too
(Ki¼ 2.30±0.22mM) (Fig. 3e). Even though oxaloacetate is
not a strong inhibitor, it has a higher inhibitory capacity
(KiOAA/KmPyr¼ 7.7) compared to malonate (KiMalon/KmPyr¼ 90;
considering a Ki¼ 27mM (ref. 35)). Although it is unlikely that
malonate (and perhaps oxaloacetate) play an important role in
the regulation of rabbit L-LDH activity, it allosterically inhibits
the enzyme, and this interaction is explained by its structural
similarity with pyruvate.
Metabolic network neighbours are most likely inhibitors.
Metabolites which are metabolically derived from each other are
structurally more likely similar as compared to more distal
metabolites that underwent more enzymatic conversions
(Fig. 4a). Indeed, structural similarity clusters strongly reﬂected
topological distances within the inhibition network (Fig. 4b,
P value 1.64e-99, t-test). Structural analogues are hence typically
found within the close metabolic neighbourhood (Fig. 4b,
Supplementary Fig. 3). Consistently, we ﬁnd that the closer the
metabolite is topologically to an enzyme, the more likely it is an
inhibitor (Fig. 4c, P value 1.91e-14, t-test). As a consequence,
Table 1 | Crystallographic data and reﬁnement statistics.
Ligand NADHþ oxaloacetate Malonate
Space group P21 P21
Cell dimensions
a, b, c (Å) 72.373, 138.763, 74.567 70.806, 76.952,118.858
a, b, g (o) 90, 110.12, 90 90, 96.48, 90.0
Resolution (Å) 1.87 1.58
Rmerge, % 10.3 (75.1) 6.9 (100.2)
Total number of observations 741,462 (42,498) 318,978 (18,851)
Unique reﬂections 112,079 (7,366) 155,035 (9,932)
Completeness, (outer shell)% 98.9 (87.7) 89.7 (78.5)
I/sI (outer shell) 14.00 (2.70) 8.00 (0.80)
oI4 half-set correlation 99.7 (56.9) 99.7 (33.4)
Reﬂections used for reﬁnement 112,037 147,320
Geometry: Ramachandran favoured, allowed, outliers, % 98.18, 1.82, 0.0 98.18, 1.82, 0.0
Rms deviation from ideal values for bond lengths (Å) and bond angles (o) 0.012/1.227 0.018/1.734
Number of non-hydrogen atoms in reﬁnement 11,166 11,632
Reﬁnement (R/Rfree 5% reﬂections in test set), % 17.00/19.90 17.40/20.30
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inhibitors are enriched to occur within metabolic pathways
(Supplementary Figs 4,5). Metabolic feedback and feed-forward
loops emerge hence most likely within metabolic pathways for
structural reasons.
Most connected metabolites are frequent inhibitors. Glycolysis,
gluconeogenesis and nucleotide interconversions were the most
inhibited and inhibiting metabolic pathways (Fig. 4d,e). While
this particular result could be the consequence of a testing bias,
we conﬁrmed a highly signiﬁcant correlation between the number
of inhibitory interactions and metabolic reactions for metabolites
across the network, revealing that central metabolites are
the most frequent inhibitors (Fig. 4f, P value 2.2e-16, r 0.627,
Pearson’s correlation). Indeed, the more central or essential a
metabolic enzyme, the more likely its substrates are inhibitors
(Fig. 4g, P value ¼ 1.71e-11, t-test). Furthermore, all of the most
frequent inhibitors were essential metabolites (Fig. 4h), and
metabolites that function across subcellular compartments inhibit
far more enzymatic reactions, as other metabolites (Fig. 4k).
Indeed, this ﬁnding is metabolically plausible for the reason that
these metabolites are also the frequent substrates. We asked
whether metabolite essentiality and structural similarity could
be one explanation. Indeed, essential metabolites were more
structurally similar to each other, compared to non-essential
metabolites, which reﬂects their central localization in the
network (Supplementary Fig. 6). Such a situation could emerge if
evolution selects against enzyme inhibitors; a negative selection
would be much more effective on non-essential metabolites
compared to essential metabolites. Indeed, essentiality was found
to be only a factor for metabolites to be inhibitors but not for
enzymes to be inhibited. Although enzymes are more likely to be
essential when they are implicated in more metabolic reactions39,
they were inhibited irrespectively of whether they are essential or
are not essential (Fig. 4i,j).
Subcellular compartmentalization reduces enzyme inhibition.
Metabolic organization in the seven human (organellar) compart-
ments may reduce unwanted enzyme–inhibitor interactions40.
We started with simulating random compartmentalization.
Allowing enzymes and inhibitors to participate in multiple
compartments as in the human metabolic network, the number
of inhibitory interactions is reduced as more hypothetical
compartments are introduced, an effect that saturates after
8–10 compartments (Fig. 5a). In a network that omits multiple
localized metabolites, the effects are more dramatic (Supplementary
Fig. 7a).
The metabolic network can however not randomly compart-
mentalize due to its chemical connectivity. We therefore examined
the effect of compartmentalization upon including enzyme
localization to cytoplasm, Golgi apparatus, lysosome, mitochondria,
nucleus, endoplasmic reticulum (ER) and peroxisome to the
inhibitor network. The maximum number of inhibitory interac-
tions takes place within cytoplasm followed by mitochondria, the
two compartments that host also the highest number of metabolic
reactions (Fig. 5b). Accounting for multiple metabolite localiza-
tions, the total number of inhibitory interactions is found
signiﬁcantly reduced for organelle-localized reactions, even after
correcting for their smaller size (Fig. 5c,d). Only 6% of cytoplasmic
inhibitors loose co-localization with the enzyme they inhibit, but
38% of mitochondrial, 54% of ER, 65% of peroxisomal, 59% of the
nuclear, 67% of lysosomal and 71% inhibitors produced in the
Golgi (Fig. 5d). As a consequence, compartmentalization reduces
2% of inhibitory interactions within the cytoplasm, but 21% in
mitochondria, 43%, in the ER, 49% in the peroxisome, 46% in the
nucleus, 60% in the lysosome and 54% in the Golgi. A speciﬁc
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organellar localization does explain this result. The number
of inter-compartment interactions per inhibitor was constant
across all compartments including cytoplasm (Supplementary
Fig. 7b). However, the ratio of inter-compartment inhibition
versus total inhibition is substantially lower for organellar enzymes
(Supplementary Fig. 7b). If excluding mulitpe-localized metabolites,
this picture further substantiates (Supplementary Fig. 7c). Next, we
compared the number of inhibitors within and between compa-
rtments, and upon correcting for sample size, expressed the results
as a compartment inhibition network (Fig. 5f). Only in the
cytoplasm we detected the enrichment of inhibitors as expected
from the structural similarity that prevails in the metabolic
neighbourhoods (Fig. 4c). Inhibitors did however not enrich in
any of the organelles. As a control experiment, we compared the
inhibitory potential if organellar enzymatic reactions would localize
to another compartment. A change of localization would result in a
signiﬁcant enrichment of inhibition (illustrated as inhibition
between compartments) (Fig. 5f). Hence, the effect that enzyme
inhibitors are enriched within the close metabolic neighbourhood is
counteracted by compartmentalization.
Discussion
Enzyme inhibition has been studied for decades in the context of
enzyme function and in the regulation of metabolism, but there is
still little information about its global nature. However,
enzymologist collected in vitro data about enzyme function in
thousands of carefully conducted small-scale experiments over
a century. A data set of comparable depth not available for
any other biological problem. We took the assumption that the
basic principles of enzyme inhibition will be the same across
species. The cross-species inhibitor information that could be
mapped onto the topology of the human metabolic network
reconstruction—itself based on experimental results derived
from multiple species—is estimated to be the result of more
than 9,000 years of single-person experimental work, and
our network incorporates work of418,000 research publications.
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The large size was required to outweigh, or at least statistically
deﬁne, the testing bias that exists in the biochemical literature.
The high coverage indeed alleviated a selective bias against a
certain enzyme class or reaction mechanism, so that all human
EC classes are equally well covered (Fig. 1). The inhibitor space
instead is restricted to commercially available metabolites and
hence, is less complete. Nonetheless, also here a critical number of
inhibitors represent each HMDB metabolite class (Fig. 1d) and
no coverage bias caused by the purchase cost of the chemicals
(a proxy of its market properties) was detected (Supplementary
Fig. 8). Another potential bias could be caused by the situation
that competitive inhibitors are easier to be predicted compared
to allosteric inhibitors; however, the number of incorporated
studies that base on structural prediction is marginally small.
Finally, there is a coverage bias, because popular enzymes
or metabolites like ATP have been studied more often than
other metabolites. Here, we apply a number of statistical methods
that correct for sample size, and discuss this bias in all cases
where it is relevant.
Our network is only qualitative, as we were unable to
incorporate quantitative kinetic information (that is, Ki,
Km values). First, for only a fraction of the inhibitors this
information is available, second our network is cross-species and
enzyme constants vary between species, and third, many
enzymatic constants differ substantially if determined by more
than one lab (Supplementary Fig. 9). The latter situation is most
likely explained by differences in experimental conditions, pH in
particular. This result shows however that enzyme inhibition
might form a dynamic network also biologically, as conditions
like pH change also in vivo and differ between organelles.
Consequently, enzyme inhibitors, even those that have strong
inhibitory constants, might be biologically relevant only under a
subset of conditions, while supposedly weak inhibitors could
conditionally become relevant inhibitors. In any case, weak
inhibitors have to be considered a metabolic constraint due to the
fact that thousands of them act in parallel.
Metabolite–enzyme inhibition is required to regulate enzyme
function. Our data indicate however that it is not necessarily
evolved for this purpose, and that only a fraction of metabolite–
enzyme interactions are indeed of regulatory nature. Instead, a
majority of inhibitory interactions seem to emerge as a property
caused by metabolite stereochemistry. Most of enzyme inhibition
is to be traced to metabolites that possess signiﬁcant structural
similarity to the enzymes metabolic substrates, and we ﬁnd that
inhibitors enrich as a function of the metabolic network’s
topological distance. Notably, our data show that not only
competitive inhibition, but also allostery is affected by chemical
structural constraints. One-third of allosteric inhibitors do
possess signiﬁcant structural similarity to the inhibited enzyme’s
substrates. Identifying an illustrative case with L-LDH, we
determined its molecular structure by X-ray diffraction when
bound to two non-competitive metabolites. We found that both
inhibitors, one of them not common to the mammalian cell, bind
to L-LDH as a consequence of their structural similarity to a
biological relevant L-LDH regulator, pyruvate.
A recent and illustrative example for metabolic constraints
caused by enyzme inhibition concerns glyceraldehyde-3-phos-
phate dehydrogenase and PK, that promiscuously produce
4-phospho-erythronate and 2-phospho-L-lactate. These metabo-
lites need to be removed by speciﬁc clearance enzymes in order
that glycolysis and pentose phosphate pathway (PPP) are not
inhibited41. Enzyme inhibition can have hence negative
consequences for metabolism to the extent inhibitor clearance
is frequently observed as a part of ‘metabolite repair’ processes
that are energetically costly42. One may argue however that many
enzyme inhibitors have relatively weak inhibitory constants.
One has to take into consideration however that the metabolites
which are part of the human metabolic network are the ones that
prevailed, while strong inhibitors as the ones aforementioned
were negatively selected and have not been retained. Consistently,
across the network, we ﬁnd that a highest number of inhibitions
is observed for the most important and most connected
metabolites that are the most difﬁcult to negatively select.
A further prediction derived from this situation is that the
activity of many metabolic enzymes in vivo will be lower as the
activity estimated in in vitro kinetic experiments. One illustrative
example is TPI, a central enzyme in glycolysis. In vitro considered
a ‘prefect enzyme’ limited only by the diffusion rates of its
substrates, it has been suggested that TPI is multiple times more
active in cells than is needed for glycolysis43. In vivo however,
a reduction of TPI activity by just 20% is sufﬁcient to affect
yeast metabolism44.
If enzyme inhibition emerges for structural reasons, it follows
that structural similarity could form a basis for the evolutionary
origin of regulatory mechanisms. An example is identiﬁed in the
inhibition of fructose-1,6-bisphosphatase by fructose-2,6-bispho-
sphate, a regulatory metabolite in eukaryotic cells. Escherichia
coli, like most bacteria, do not possess fructose-2,6-bisphosphate
(F26BP), so the E. coli enzyme can’t have evolved to be regulated
by the compound. Yet, F26BP, structurally similar to fructose-1,6-
bisphosphate does inhibit E. coli fructose-1,6-bisphosphatase
in vitro. In eukaryotic cell that use F26BP for regulation, its
binding afﬁnity is increased, especially in the presence of AMP, a
non-competitive inhibitor for fructose-1,6-bisphosphatase8,45,46.
Structurally driven enzyme inhibition, in particular its high
frequency in affecting virtually all enzymes, might contribute to
difﬁculties in designing synthetic metabolic pathways47. To
illustrate the magnitude of the problem, we have conducted a
computational Gedanken experiment and expanded the human
metabolic network by the reactions of the E. coli reconstruction
(iJO1366)48. The newly introduced 112 bacterial metabolites
would serve as inhibitors for 494 (80%) of the human reactions.
Vice versa, 313 human metabolites are annotated inhibitors for
289 E. coli speciﬁc biochemical reactions. The network expansion
would hence both inhibit the existing as well as the newly
introduced enzymes. Support for the relevance comes from
synthetic biology, where engineered biosynthetic pathways are
regularly of low activity, and in many cases it is required to
metabolically evolve the host so that the product is formed47,49,50.
A classic example was to render yeast an efﬁcient producer of
the anti-malaria drug artemisinic acid, which took more than
a century of single-person’s work to achieve51. Localizing
newly introduced metabolic pathways to organelles increases
metabolic efﬁciency, a strategy that shields enzymes from their
inhibitors47,52. In this context, the genome-scale importance of
enzyme activators is not understood, and warrants a systematic
investigation. According to the data as stored in BRENDA,
non-catalytic enzymatic activators are far less frequent as
enzymatic inhibitors.
Several mechanisms reduce the problem of enzyme inhibition
by separating biochemical reactions from each other. Metabolic
oscillations for instance, as observed within central carbon
metabolism, separate reactions by time. In yeast, the occurrence
of metabolic oscillations has been associated with the separation
of oxidative from fermentative metabolism which at any given
time reduces the number of active reactions53. Second,
predominant in microbial communities but also found in
eukaryotic cells, cooperative exchange of metabolites enables
cells to specialize in metabolism. As a consequence, in each
cooperating communal cell, only subsets of the metabolic
reactions need to be active54. We speculate that reducing the
problem of enzyme inhibition could be one contributing factor
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms16018 ARTICLE
NATURE COMMUNICATIONS | 8:16018 |DOI: 10.1038/ncomms16018 | www.nature.com/naturecommunications 9
that adds to the success of metabolite exchange interactions
in microbial communities. Studying eukaryotic metabolism, we
ﬁnd the subcellular distribution of metabolic reactions in
organelles is inﬂuenced by the presence of inhibitors. There are
several beneﬁts of cellular compartmentalization including
separation of metabolite from competing reactions55 and
managing toxic intermediates from inhibiting growth56. Our
data show that metabolism exploit subcellular compartmentali-
zation also to reduce enzyme inhibition. Despite inhibitors
and structurally similar metabolites enrich in the neighbourhood
of a metabolic enzyme (Fig. 4), the distribution of enzymes
prevents such an enrichment in all organelles (Fig. 5). Overall,
compartmentalization in the human network reduces the number
of inhibitory metabolite–enzyme interactions by up to half, and
appears hence to be a highly effective global counteraction against
metabolic enzyme inhibition.
In summary, we have constructed a global network of inhibitory
metabolite–enzyme interactions by computationally merging
detailed enzymological information with a genome-scale human
metabolic network reconstruction. The obtained metabolite–
enzyme inhibitor network pictures general principles that underlie
enzyme inhibition as obtained on a cross-species basis. We ﬁnd
that thousands of inhibitory interactions render, in essence, every
biochemical process sensitive to metabolic inhibition. Most
inhibitory interactions emerge as consequence of a ﬁnite structural
diversity that exists within the central parts of the metabolome.
Structurally driven enzyme inhibition is mostly of competitive,
but partially also of allosteric nature. We exemplify the latter
by detailed enzymological and structural analysis of L-lactate
dehydrogenase in complex with two allosteric inhibitors, whose
inhibitory properties are explained by their structural similarity to
its typical allosteric regulator, pyruvate. Finally, enzyme inhibition
emerges mostly in the metabolic neighbourhood of the inhibited
enzyme, is dominated by the most conserved and important
metabolites, which speciﬁcally interact with particular enzyme
classes dependent on their chemical nature. This situation is
associated with compartmentalization in the eukaryotic cell that
reduce metabolic enzyme inhibition up to half and speciﬁcally, by
preventing an enrichment of enzyme inhibition within the
metabolic neighbourhood of the eukaryotic organelles. While
metabolic enzyme inhibition is key for the self-regulation of
metabolism, its primary cause is hence the chemical structure of the
metabolome. Many non-catalytic metabolite–enzyme interactions
mount to a constraint for the function of cellular metabolic
network, so that the cells evolved mechanisms to limit the number
of unwanted and inhibitory metabolite–enzyme interactions.
Methods
Reconstruction of an enzyme-inhibition network on the genomic scale.
Curation and mapping strategy: An enzyme-inhibition network was constructed by
mapping enzyme inhibitory information curated from experimental data collected
in the BRaunschweig ENzyme DAtabase (BRENDA)16 onto the human genome-
scale metabolic model (Recon2)17. For every enzymatic reaction of the Recon2
model (in total 747 distinct EC numbers), a list of all inhibitors (in total 30,107 in
which an inhibitor with multiple names appear multiple times; redundancy was
removed by curation) were extracted from the BRENDA database. These
compounds were assigned unique ID accounting to the Kyoto Encyclopedia of
Genes and Genomes (KEGG)57, human metabolome database (HMDB)22 on the
basis of entries from KEGG and HMDB databases by using merging algorithms58
(http://cts.ﬁehnlab.ucdavis.edu/). Unique metabolite IDs (KEGG, HMDB) were
then assigned to Recon2 metabolites, and mapped with the list of inhibitors. In
total, 682 compounds, out of 30,107 BRENDA inhibitors, were successfully
mapped to the Recon2 metabolites. These 682 metabolites inhibit 621 enzymatic
reactions as contained in the Recon2 model. In the enzyme-inhibition network, a
metabolite and an enzyme node were connected if a metabolite is an inhibitor for
the enzyme, constituting in total 5,989 edges in the network. Information related to
different kind of inhibitions including competitive, uncompetitive or
noncompetitive for inhibitors of the enzyme-inhibition network was extracted
from the information stored in BRENDA. A similar approach was followed for 289
E. coli-speciﬁc enzymes (according to iJO1366 metabolic reconstruction48). A list of
6,028 inhibitors was extracted from BRENDA for 289 E. coli-speciﬁc enzymes.
These inhibitors were assigned to KEGG IDs and mapped with metabolites from E.
coli model. iJO1366 model has in total 1,138 compounds, of which 851 compounds
have KEGG ID, and 450 compounds were inhibitors.
Classes of enzymes and inhibitors. Classiﬁcation of 621 enzymes and 628
inhibitors was conducted following KEGG nomenclature57 for enzymes and
HMDB for small molecules22. Inhibitors are classiﬁed among total 17 HMDB
Superclasses (Supplementary Table 2). Three superclasses including (1) Aromatic
Heteropolycyclic Compounds, (2) Aromatic Heteromonocyclic Compounds and
(3) Aromatic Homomonocyclic Compounds were merged to one group named
(i) Aromatic Cyclic Compounds. Additionally, eight other superclasses with a low
number of metabolites each ((1) Alkaloids and Derivatives, (2) Aliphatic
Homomonocyclic Compounds, (3) Aliphatic Heteropolycyclic Compounds,
(4) Benzenoids, (5) Homogeneous Non-metal Compounds, (6) Organophosphorus
Compounds, (7) Organooxygen Compounds, and (8) Aliphatic Heteromonocyclic
Compounds) were merged to a single group named (ii) Others compounds. The
other Superclasses were (iii) Nucleosides, Nucleotides, and Analogues, (iv) Organic
Acids and Derivatives, (v) Amino Acids, Peptides and Analogues, (vi) Aliphatic
Acyclic Compounds, (vii) Carbohydrates and Carbohydrate Conjugates, and
(viii) Lipids. HMDB database entry is according to Version 3.5. It is however also
important to note that there is inconsistencies in taxonomical classiﬁcation of
compounds with respect to different databases such as HMDB22, KEGG57,
ChEBI59 or LipidMaps60. Although HMDB compounds taxonomy uses thousands
of chemical rules to classify compounds in functional categories, there are still
some issues in assigning proper group to different compounds. For example, amino
acids which are also aromatic compounds are placed in Amino Acids, Peptides and
Analogues superclass, so that redundancy is prevented.
Enrichment of class of inhibitors inhibiting classes of enzymes. Inhibitors were
counted for each class of compounds, and inhibitory interactions for each class of
enzymes. The ‘phyper’ function in R was used for Hypergeometric test. P value 0.05
was used as signiﬁcance threshold. False discovery rate (FDR) for inhibition of a
class of enzymes by a class of inhibitors was calculated as follows. First, inhibitors
were randomly assigned to each inhibitor class, and this process was repeated for a
hundred times. Then, an enrichment analysis for inhibition of a class of enzymes
was performed on randomly assigned inhibitor classes. Finally, if P value of
inhibition was better for a random group of inhibitors than the original inhibitor
class then the counter was increased. FDR¼ counter/100.
Compound similarity. Out of 682 inhibitors of the enzyme-inhibition network,
structure-data ﬁles (SDF) were available for 638 metabolites in the PubChem
database. Pairwise compound comparisons for all pairs of inhibitors were
performed using with PubChem ﬁngerprints (fpSim)30, as well as other measures
of similarity such as Drug molecule similarity derived by molecular ﬁngerprints
(calcDrugFPSim31), Maximum common substructure (Tanimoto Coefﬁcient,
Overlap Coefﬁcient32) and Pairwise compound comparisons with atom pairs
(cmp.similarity30).
Metabolite structural similarity calculations. To examine similarity between an
inhibitor and substrates, a list of all substrates of the enzyme was extracted from
the network reconstruction17. Then, for each inhibitor of this enzyme, the pairwise
similarity to each of these enzyme metabolites was calculated, and only the best
match considered as the similarity value. Further, to calculate similarity between
inhibitor and any random compound, a list of random compounds of equal
number as the enzymes metabolites was selected randomly from the list of all
inhibitory metabolites. This process was repeated 50 times for both inhibitors and
random metabolites. For example, a metabolite is an inhibitor for 5 enzymes
(E1, E2, E3, E4, E5), that have 2, 3, 3, 2, and 4 substrates each respectively,
constituting in total a list of 14 substrates connected to the inhibitor. First, the
similarity between the inhibitor and all 14 substrate metabolites is calculated. Then,
14 metabolites are randomly selected from the inhibitor network and their
structural similarity compared with the inhibitor mapped to the enzyme. This
random sampling is repeated 50 times, and eventually, 50 times the similarity score
of the most similar random compound is plotted against the similarity score of the
most similar enzyme metabolite.
Within and between metabolic pathway similarity. Pathway to pathway
similarity was calculated by extracting a list of pathways in accordance to the
Recon2 model17. Then, for each metabolite the score between all compounds of
pathways was pairwisely calculated, the shared compounds (that is, ATP, NADH,
and so on), as well as metabolites that are not inhibitors in the network, were
excluded. The similarity between two pathways is then expressed as the average
score of all pairs. On the basis of number of inhibitions from one metabolic
pathway to another, excluding the common metabolites, P values were calculated
for every pair of metabolic pathways using hypergeometric test. Inhibition from
one pathway to the other considered signiﬁcant when P valueo0.01.
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Metabolite and enzyme essentiality. For every inhibitor, a list of genes directly
involved in its metabolism was extracted from the reconstruction17. If any gene in
the list is essential according to cell-speciﬁc essential genes61, then the metabolite
was considered essential. Following the similar strategy for enzymes, a list of all
genes associated with an EC number was used. If any gene in the list is essential
according to cell-speciﬁc essential genes61, the enzyme was considered essential.
Compartment–compartment inhibition. In the Recon2 model, there are in
total seven compartments including Cytoplasm, Golgi apparatus, Lysosome,
Mitochondria, Nucleus, ER and Peroxisome17. Enzymes and inhibitory interactions
were assigned to these compartments according to the localization of its
participating pathways. A 7 7 numerical matrix of metabolites inhibiting
compartmentalized enzymes was assembled and used to deﬁne, for every pairwise
comparison between compartments, trans-compartment inhibiting enzymes.
Metabolites shared between compartments were excluded as indicated. For self-
inhibition within a compartment, compartment-speciﬁc inhibitors are considered.
These counts were used to calculate signiﬁcance of inhibition between a pair of
compartments using hypergeometric test. P valueo0.05 was used as signiﬁcance
criterion to construct the compartment–compartment-speciﬁc inhibition network.
Additionally, a FDR between a pair of compartments was calculated. First, for each
compartment, the same number of compounds was randomly assigned, and this
process was repeated for a hundred times. Then, an enrichment analysis for
inhibition within and between a pair of compartments was performed following the
same strategy as for the randomly assigned compounds. Finally, if the P value of
inhibition between a pair of compartments is better for a random set of inhibitors
compared to the original inhibitors then the counter was increased.
FDR¼ counter/100.
Simulating the effect of a random compartmentalization. To examine the
overall impact of compartmentalization on inhibition, a number of random
compartments (‘rc’, between 2 and 50) were created. First, for each metabolite ‘m’
and enzyme ‘e’ of the inhibition network (Fig. 1b), the number of compartments ‘n’
(between 1 and ‘rc’) in which ‘m’ and ‘e’ are allowed to participate was
randomly selected following a power-law distribution (‘function(x, a¼ 0.5, b¼ 1)
a*b^a/x^(aþ 1)’). Then, ‘m’ and ‘e’ was placed in ‘n’ random compartments.
Finally compared to the total 5,989 interactions of the inhibition network (Fig. 1b),
the total number of inhibitory interaction removed due to ‘rc’ compartments was
counted. The entire process was repeated for 50 times.
Selection against unwanted inhibition. To examine whether the selection of
unwanted inhibitions within compartments affected competitive and allosteric
inhibition modes differentially, we used the set of ‘gold standard’ examples for
which the type of inhibition is known with the greatest reliability (Fig. 2a). We
calculated a ratio that compares the occurrence of competitive versus allosteric
inhibition in a compartment-dependent manner. A ratio of substrate-inhibitor
(S-I) pairs within the same compartment, versus the S-I pair within the different
compartment, is more pronounced for competitive inhibition compared to
allosteric inhibition (Fig. 5e).
Kinetic characterization of L-LDH from rabbit muscle. The activity of L-LDH
was measured spectrophotometrically following the NADH oxidation at 340 nm at
37 C in a 50mM buffer Na2HPO4 pH 7.4 (ﬁnal volume 150 ml). The reaction
mixture contained 1mM NADH, 50 ng of L-lactate dehydrogenase from
rabbit muscle (Roche) and pyruvate was added to start the reaction. For Km
determinations, a saturation curve of pyruvate was generated by varying the
concentrations from 0 to 3mM at saturating concentrations of NADH (1mM). For
the saturation curve for NADH, this substrate was varied from 0 to 1mM at
saturating concentrations of Pyruvate (3mM). For Ki determinations, similar
experiments for Km determinations were done in the presence of different
concentrations of oxaloacetate (0–7.5mM). For the Ki determination of
oxaloacetate versus pyruvate, the reaction mixture containing NADH, L-LDH and
oxaloacetate was incubated for 1min and then the reaction was started by
adding pyruvate. All the substrates and inhibitor were prepared fresh and the
oxaloacetate stock solution was kept on ice maximum for 2 h. The kinetic data
was analysed using the software Origin 9.0.
Crystallization of L-LDH. The L-lactate dehydrogenase from rabbit muscle
(Roche) was buffer exchanged into HEPES 40mM pH 7.5 using a centrifugal
concentrator (Amicon Ultra-4 Centrifugal Filter Unit with Ultracel-30 membrane)
and then adjusted to a ﬁnal concentration of 5mgml 1. For the L-LDH
co-crystallized with NADH, 5mM of the cofactor was mixed with the protein
before the crystallization experiments. The crystals were grown using the
vapour diffusion method at 20 C in a solution containing 10% wt/v PEG 3350,
50mM Bis-tris propane pH 6.5 and 100mM NaF. The crystals appeared after 24 h
reaching their maximum size after 4 days. The crystals were cryoprotected by
adding the reservoir liquor supplemented with 20% w/v PEG 400 and 5mM
oxaloacetate before ﬂash freezing in liquid nitrogen. In the case of the L-LDH
co-crystallized with malonate, the protein was buffer exchanged as mentioned
above. The crystals were grown in a buffer containing 0.1M sodium malonate
and 10% w/v PEG 3350. The crystals were cryoprotected by adding the reservoir
liquor supplemented with 20% w/v PEG 400 and 2.5mM oxaloacetate and then
frozen immediately in liquid nitrogen.
Crystallization data collection and structure analysis. Data for the L-LDH
crystals with malonate were collected at Diamond Light source on station I04-1,
and data for the L-LDH crystals with NADH and oxaloacetate were collected on
station I03. Both data sets were collected at 100K. The structures were solved by
molecular replacement (PHASER) using coordinates for rabbit muscle L-LDH in
which all ligands and water molecules were removed (PDB code 3H3F (ref. 62)).
The structures were reﬁned using PHENIX and ligands built into density using
COOT. The diffraction data were processed avoiding images with radiation
damage. The reﬁnement and crystallographic data are summarized in Table 1.
Additional software tools. SOAP from BRENDA (http://www.brenda-enzymes.org/
soap.php)16 was used to fetch inhibitors for every enzyme. The displ, dislnorm,
dispois and disexp functions from R package poweRlaw63 were used to ﬁt power-law,
log-normal, Poisson and exponential distributions respectively for the nodes of
enzyme-inhibition network as well as for a random network which was constructed by
function erdos.renyi.game from R package igraph64. Shortest path length for
metabolites and enzymes in the enzyme-inhibition network was calculated by function
shortest.paths. Word cloud of inhibitors was made by wordcloud library in R.
Alignment of substrate and inhibitor in active site of enzymes was done by PyMOL
tool. The ﬁgures were prepared using Adobe Illustrator. Function cor.test in R was
used for Pearson’s product–moment correlation. Function t.test in R was used for
Welch two sample t-test.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author on reasonable request. The coordinates and
structure factors for the malonate and oxaloacetate with NADH complexes
with rabbit muscle L-Lactate dehydrogenase have been deposited with the PDB
accession codes 5NQB and 5NQQ, respectively. More detailed information
about the Inhibition Network, Inhibitors, Enzymes, Competitive inhibition,
Noncompetitive inhibition, Uncompetitive inhibition and Pathways are available
in Supplementary Data 1.
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